EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Microbot Medical Inc (MBOT) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Microbot Medical Inc $0.96, price $1.31, upside -26.7%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US59503A2042

MM Microbot Medical Inc logo Thin data Sep 23, 2026

Microbot Medical Inc

MBOT · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.9605 · Overvalued (−27%)
!Quality 25/100
!Weak Growth (revenue 5y −39.4 %/yr)
!Low debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 3/100
!Insider activity 40/100
!Evidence only low, so the estimate is less certain
Watch Microbot Medical Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.95 $0.8300 Fair Value $0.9605 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.8300 – $8.95 · fair‑value band $0.6375 – $1.20 · the $1.31 price screens above the $0.9605 fair value. 4 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow Microbot Medical in your weekly email

Every Wednesday you see whether Microbot Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.

Show more

Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts

Stock analysis

Microbot Medical Inc (MBOT) currently trades at $1.31, while our model-based Fair Value estimate is $0.9605, implying the stock looks roughly 36.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.6375 (bear) to $1.20 (bull), the price of $1.31 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Microbot Medical Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$13.1M in FY2025.

Key figures

Market cap $125M · EPS (TTM) $−0.2600 · Return on equity −27.6% · Return on assets (EBIT) −107% · Operating margin −4,114% · Revenue (TTM) $105K · Free cash flow −$13.1M · Net cash $3.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −27%, MBOT screens richer than that median.

Fair Value models

Bear $0.6375 Fair Value $0.9605 Bull $1.20
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.5800 $0.7700 $1.15 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.5800 $0.7700 $1.15 54

Open the full fair value analysis →

Notify me when MBOT reaches fair value

Put MBOT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 33 · Market factors (momentum, volatility) 11

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 79
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 29
Calm price path (market factor)
Momentum 6
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−88.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−55.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−39.4%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,041.9% (2010) → −31,384.6% (2015)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MBOT screens 36% overvalued. Compare with Intuitive Surgical, Inc →

Compare Microbot Medical Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −27% · Below median
Profitability
Return on assets −18% · Bottom 25%
Growth and dividend
Revenue growth 0% · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 1.61× · Cheaper than median
PEG 0.70× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.70 €159.17 +10%
Medline Inc MDLN $34.30 $30.15 −12%
Becton, Dickinson and Company BDX $182.52 $103.53 −43%
Alcon Inc ALC $65.39 $39.78 −39%
ResMed Inc RMD A$31.70 A$34.87 +10%
West Pharmaceutical Services, Inc WST $375.87 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €215.80 €54.82 −75%
Straumann Holding STMN CHF 96.38 CHF 45.50 −53%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Microbot Medical Inc · Fair Value
$0.9605 −36%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Microbot Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/MBOT

Frequently asked questions

Is Microbot Medical Inc (MBOT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.9605 versus a price of $1.31, about −27% upside (overvalued).
What is the fair value of MBOT?
Our model-based fair value for Microbot Medical Inc is $0.9605 (as of Sep 23, 2026), built from audited fundamentals. The current price: $1.31.
What is the quality score of MBOT?
Microbot Medical Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Microbot Medical Inc (MBOT)?
Our model-based price target is the fair value of $0.9605 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.6375, optimistic scenario $1.20. It is a calculation from audited fundamentals, not an analyst target.
What is the Microbot Medical Inc stock forecast for 2026?
Our models put fair value at $0.9605, about −27% upside versus a price of $1.31 (overvalued). Cautious scenario $0.6375, optimistic scenario $1.20. The calculation is refreshed regularly with new filings.
What is the revenue of Microbot Medical Inc (MBOT)?
Microbot Medical Inc reported trailing-twelve-month revenue of about $105K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Microbot Medical Inc (MBOT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Microbot Medical Inc it is $0.9605 per share (as of Sep 23, 2026), against a price of $1.31. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Microbot Medical Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, MBOT trades above its calculated fair value: price $1.31, fair value $0.9605, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MBOT?
No. The price is what the market pays today ($1.31); the fair value is what the company's own numbers justify ($0.9605). For Microbot Medical Inc the two are $0.3495 per share apart. That gap is exactly why we show both numbers side by side.
How much is Microbot Medical Inc worth?
The market values Microbot Medical Inc at about $125M (market capitalisation, as of Sep 23, 2026). Per share that is $1.31; our models calculate a fair value of $0.9605 per share.
What do the bullish and bearish scenarios say about MBOT?
Our models span a range for Microbot Medical Inc: cautious scenario $0.6375, base $0.9605, optimistic $1.20 per share (as of Sep 23, 2026, price $1.31). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MBOT?
The PEG ratio of Microbot Medical Inc is 0.70 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Microbot Medical Inc (MBOT)?
Balance-sheet figures for Microbot Medical Inc (as of Sep 23, 2026): return on equity −27.6%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is MBOT from its 52-week high?
Microbot Medical Inc trades at $1.31, about 62% below its 52-week high of $3.48 and at the low of $1.31 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9605 is for.
Which stocks are comparable to Microbot Medical Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Microbot Medical Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $1.31, calculated fair value $0.9605 (−27%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MBOT calculated?
We run Microbot Medical Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9605, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Microbot Medical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Microbot Medical Inc (MBOT)?
The closing price on Sep 23, 2026 was $1.31. Our model-based fair value is $0.9605, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Microbot Medical Inc right now?
The price sits above even our optimistic bull case ($1.20). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($0.6375 to $1.20) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Microbot Medical Inc

How large is the market capitalisation of Microbot Medical Inc (MBOT)?
The market capitalisation of Microbot Medical Inc is $125M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Microbot Medical Inc (MBOT)?
Earnings per share at Microbot Medical Inc are $−0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Microbot Medical Inc (MBOT)?
The return on equity (ROE) of Microbot Medical Inc is −27.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Microbot Medical Inc (MBOT)?
On an EBIT basis the return on assets of Microbot Medical Inc is −107% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Microbot Medical Inc (MBOT)?
The operating margin of Microbot Medical Inc is −4,114% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Microbot Medical Inc (MBOT) generate?
The free cash flow of Microbot Medical Inc is −$13.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Microbot Medical Inc (MBOT) hold?
Microbot Medical Inc holds more cash than debt, $3.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Microbot Medical Inc in the live analysis

One click puts Microbot Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.